Evidence map›Paper›PMID 36962761›Full record

ArticlePLOS global public health2022

Monitoring progress towards elimination of hepatitis B and C in the EU/EEA.

Katherine C Sharrock, Teymur Noori, Maria Axelsson, Maria Buti, Asuncion Diaz, Olga Fursa, Greet Hendrickx, Cary James, Irena Klavs, Marko Korenjak and 10 more

Erratum issuedFull text read
In one paragraph

Article in PLOS global public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Katherine C SharrockNational AIDS Trust, London, United Kingdom.
Teymur NooriEuropean Centre for Disease Prevention and Control, Solna, Sweden.
Maria AxelssonDepartment of Public Health Analysis and Data Management, Public Health Agency of Sweden, Solna, Sweden.
Maria ButiLiver Unit, Valle d'Hebron University Hospital, Ciberehd del Insituto Carlos III Barcelona, Barcelona, Spain.
Asuncion DiazInstituto de Salud Carlos III, Madrid, Spain.ORCID https://orcid.org/0000-0002-8309-4270
Olga FursaCentre of Excellence for Health Immunity and Infections Copenhagen, Copenhagen, Denmark.ORCID https://orcid.org/0000-0002-1596-9880
Greet HendrickxViral Hepatitis Prevention Board, Centre for the Evaluation of Vaccination, Vaccine & Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium.ORCID https://orcid.org/0000-0002-0099-272X
Cary JamesWorld Hepatitis Alliance, London, United Kingdom.
Irena KlavsNational Institute of Public Health, Ljubljana, Slovenia.
Marko KorenjakEuropean Liver Patients' Association, Brussels, Belgium.ORCID https://orcid.org/0000-0003-4024-677X
Mojca MaticicFaculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Antons MozalevskisWorld Health Organization, Regional Office for Europe, Copenhagen, Denmark.ORCID https://orcid.org/0000-0003-2275-5909
Lars PetersCHIP, Centre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Rafaela RigoniCorrelation European Harm Reduction Network, Amsterdam, the Netherlands.
Magdalena RosinskaDepartment of Epidemiology of Infectious Diseases and Surveillance, National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.ORCID https://orcid.org/0000-0002-6256-7809
Kristi RuutelNational Institute for Health Development, Tallinn, Estonia.
Eberhard SchatzCorrelation European Harm Reduction Network, Amsterdam, the Netherlands.
Thomas SeylerEuropean Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal.
Irene VeldhuijzenNational Institute for Public Health and the Environment (RIVM), Centre for Infectious Disease Control, Bilthoven, the Netherlands.
Erika DuffellEuropean Centre for Disease Prevention and Control, Solna, Sweden.

Funding

World Health Organization 001
6 · The paper itself

Abstract

This paper presents data on selected indicators to show progress towards elimination goals and targets for hepatitis B and hepatitis C in the 31 countries of the European Union (EU) and European Economic Area (EEA). A monitoring system was developed by the European Centre for Disease Prevention and Control, which combined newly collected data from EU/EEA countries along with relevant data from existing sources. Data for 2017 were collected from the EU/EEA countries via an online survey. All countries provided responses. In 2017, most countries reporting data had not reached prevention targets for childhood hepatitis B vaccination and for harm reduction services targeting people who inject drugs (PWID). Four of 12 countries had met the target for proportion of people living with chronic HBV diagnosed and seven of 16 met this target for hepatitis C. Data on diagnosed cases treated were lacking for hepatitis B. Of 12 countries reporting treatment data for hepatitis B, only Iceland met the target. This first collection of data across the EU/EEA highlighted major issues with data completeness and quality and in the indicators that were used, which impairs a clear overview of progress towards the elimination of hepatitis. The available data, whilst incomplete, suggest that as of 2017, the majority of the EU/EEA countries were far from meeting most of the 2020 targets, in particular those relating to harm reduction and diagnosis. It is critical to improve the data collected in order to develop more effective services for hepatitis prevention, diagnosis, and treatment that are needed in order to meet the 2030 elimination targets.

Identifiers

PMID36962761
PMCPMC10022013

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read49
identifiers read10
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.